EPO and anemia (phenotype): HIF-PHIs not only promote endogenous EPO production, but also improve iron supply for hematopoiesis by promoting iron absorption from the intestinal tract and iron recirculation, and, thus, have promise for improving ESA-resistant anemia caused by iron deficiency and reducing the use of IV iron therapy [10].